Stock Price, News, Quote and Profile of MAINZ BIOMED NV(NASDAQ:MYNZ) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

MAINZ BIOMED NV

NASDAQ:MYNZ (11/27/2024, 8:55:36 PM)

After market: 0.2515 0 (-1.76%)

0.256

+0.03 (+13.78%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-70.55%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap5.60M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 65 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Company Info

MAINZ BIOMED NV

Sirius Gutenberg Park, Robert-Koch-Strasse 50

MAINZ HESSEN

P: 4961315542860

Employees: 65

Website: https://www.mainzbiomed.com/

MYNZ News

17 days ago - Mainz BioMed NVMainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

a month ago - Mainz BioMed NVMainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update...

2 months ago - Mainz BioMed NVMainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden

2 months ago - Mainz BioMed NVMainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert ...

2 months ago - Mainz BioMed NVMainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

MAINZ BIOMED NV (MYNZ)

Nasdaq Stock Screener

USA Stock Screener